Meet the Home ACR Testing Team
Home urinary ACR Testing is around the corner for Newcastle Gateshead CCG. Join this webinar on Tuesday 18th May to discover how this service will release capacity in your practice.
The Early Adopters Webinar
Newcastle Gateshead CCG are in discussions to join a programme to help shift kidney health testing from the clinic to the home across the UK. This is part of a nationally significant roll-out, delivered in partnership with Healthy.io, NHSx, the Accelerated Access Collaborative and the National Institute for Health Research.
You are invited to a webinar on Tuesday 18th May at 12pm for local PCN Directors, GPs and Practice Managers. This event will give you an opportunity to learn more about how the service works, how it integrates at a practice level and the big steps it takes towards reducing health inequalities. Attendees at this meeting will be the first to be offered a place in the initial deployment cohort, should it go live.
Healthy.io’s tried and tested technology delivers a COVID safe service, which aims to improve outcomes in kidney health testing for people with diabetes and other cohorts at risk of chronic kidney disease. Shifting testing to the patients’ home has shown to raise adherence to testing from 0% to 72% among consented untested patients, whilst minimising the traditional workload each practice has to take on to fulfil this care process.
We send ACR test kits directly to eligible patients' homes with their prior consent
Patients self-test using our test kit and smartphone app, which guides them easily
Results are analysed and uploaded to SystmOne or EMIS workflows in real time
found the test 'easy' or 'very
easy' to use
preferred testing at home
vs. testing at the clinic
would recommend this service
to a friend
Clinical-Grade Testing from Home
The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.
The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).
Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).
The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.
Barking and Dagenham CCG
Join us on the 18th May at 12pm
Secure your place in this webinar for PCN Directors, GPs and Practice Managers. On entering your details you will receive a link to join the meeting.
We hope to see you there.
Please contact [email protected] with any questions.
- Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024